S. 339 authorizes Medicare coverage for FDA-approved multi-cancer early detection screening tests starting in 2028, creating a new government-reimbursed revenue stream for diagnostic companies. The bill is in early legislative stages (referred to committee since Jan 2025) with 68 cosponsors and an identical House companion that has advanced further. Pure-play liquid biopsy developers and reference laboratories with processing infrastructure are positioned to benefit.
Impact: 4/10S339Congressional Bill